根据提交给美国证券交易委员会（SEC）的文件显示，阿泰贝克利公司（Ataibeckley Inc）在特定情况下若交易终止，将需向礼来公司（Eli Lilly）支付高达1.043亿美元的终止费用。
该文件详细阐述了触发此项财务义务的具体情形。尽管协议条款未完全公开，但此类安排通常在并购或重大合作交易中出现，旨在为交易各方提供一定保障。巨额终止费的设定，往往反映出交易本身的重要性和复杂性。
这一条款的披露，让市场得以窥见双方谈判中的风险分配机制。对于阿泰贝克利而言，这意味着在特定条件下退出交易将承担显著成本；而对礼来公司来说，则获得了一定程度的经济补偿保障。此类安排在医药行业的许可或收购交易中并不罕见，尤其是在涉及潜在重磅资产时。
文件并未进一步说明可能触发付款的“特定情况”具体为何，也未透露双方潜在交易的性质与规模。投资者通常密切关注此类监管文件，以评估公司可能面临的财务承诺与潜在风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.